TIMP3 rs121918348: Sorsby Fundus Dystrophy Genetics
The rs121918348 variant is an extremely rare missense alteration located in the TIMP3 gene on chromosome 22. It results in a serine-to-cysteine amino acid substitution (p.Ser181Cys) in the tissue inhibitor of metalloproteinases 3 protein. Clinically, this variant is classified as pathogenic for Sorsby fundus dystrophy, an autosomal dominant retinal disorder characterized by choroidal neovascularization, extracellular matrix thickening, and progressive central vision loss.
What each genotype means
Typical risk profile
You carry two copies of the standard allele and do not have the specific p.Ser181Cys variant in the TIMP3 gene. This genotype is not linked to Sorsby fundus dystrophy or early-onset choroidal neovascularization caused by this variant. Your baseline risk for retinal and macular health remains consistent with that of the general population.
Carried by more than 99.99% of individuals across all global populations.
Elevated risk of Sorsby fundus dystrophy
You carry one copy of the pathogenic p.Ser181Cys variant in the TIMP3 gene. In scientific literature, carrying a single altered copy is strongly associated with autosomal dominant Sorsby fundus dystrophy, a rare retinal condition typically manifesting in mid-adulthood with central vision changes, choroidal neovascularization, or macular atrophy. Discussing these findings and periodic comprehensive eye examinations with an ophthalmologist or genetic counselor is advised.
Extremely rare, observed in fewer than 1 in 100,000 individuals in large reference databases such as gnomAD.
Elevated risk of Sorsby fundus dystrophy
You carry two copies of the p.Ser181Cys missense change in the TIMP3 gene. Because Sorsby fundus dystrophy follows an autosomal dominant inheritance pattern, having the variant is associated with characteristic progressive macular degeneration and subretinal neovascularization. Biallelic homozygosity is exceptionally rare in the scientific literature, and individuals with this genotype should review their eye health with an ophthalmologist or clinical genetics professional.
Virtually absent in general population databases, with expected frequencies far below 1 in 1,000,000.
Genomic Location and Variant Classification
The single nucleotide polymorphism designated as rs121918348 represents a point mutation within the TIMP3 gene situated on chromosome 22q12.3. Specifically, it involves a single base substitution (frequently documented as c.542C>G or related codon alterations leading to p.Ser181Cys, historically also indexed as Ser204Cys when including the signal peptide). This change replaces a polar serine residue with an extra cysteine residue in the mature protein's C-terminal domain. In genetic databases such as ClinVar and dbSNP, this specific variant is classified as pathogenic for autosomal dominant Sorsby fundus dystrophy. Because typical wild-type TIMP-3 depends on an exact pairing of twelve cysteine residues to form six critical intramolecular disulfide bonds, the introduction of an unpaired thirteenth cysteine fundamentally disrupts normal tertiary protein conformation.
Biological Function of the TIMP3 Gene
The TIMP3 gene encodes tissue inhibitor of metalloproteinases 3, a specialized matrix-associated protein. Unlike other members of the TIMP family that diffuse freely throughout extracellular fluids, TIMP-3 tightly binds to the extracellular matrix, particularly within ocular tissues such as Bruch's membrane beneath the retinal pigment epithelium. TIMP-3 regulates matrix remodeling by inhibiting matrix metalloproteinases (MMPs) and ADAM family proteases, while also regulating angiogenesis by blocking vascular endothelial growth factor receptor 2 (VEGFR2). When an aberrant cysteine residue is introduced—as seen with rs121918348—the protein forms abnormal intermolecular disulfide aggregates. This leads to reduced protein turnover, pathological thickening of Bruch's membrane, disrupted nutrient transport to the retina, and elevated rates of retinal pigment epithelial cell apoptosis.
Clinical Associations and Disease Progression
The primary clinical phenotype associated with the rs121918348 variant is Sorsby fundus dystrophy (SFD), a rare, progressive form of central macular degeneration. The condition is inherited in an autosomal dominant pattern, meaning a single copy of the variant allele is sufficient to confer disease susceptibility. Clinical symptoms typically manifest in early to mid-adulthood, commonly between the ages of 35 and 45. Initial symptoms frequently involve night blindness or sudden visual distortion caused by subretinal choroidal neovascularization (abnormal new blood vessels leaking under the retina), often mirroring the wet subtype of age-related macular degeneration. Without early intervention to control choroidal neovascularization, rapid progression to disciform macular scarring and central vision loss occurs, often subsequently affecting the contralateral eye within months to years.
Population Frequency and Research Context
In large reference populations cataloged by the Genome Aggregation Database (gnomAD), the rs121918348 variant is exceptionally rare, displaying an overall minor allele frequency of less than 0.00001 (below 1 in 100,000 alleles). Sorsby fundus dystrophy itself is an orphan genetic condition documented only in limited multi-generational pedigrees worldwide. Because of its extreme scarcity in the general populace, the variant is almost never encountered on routine recreational or population-screening microarrays. While wide-scale genome-wide association studies (GWAS) frequently study common non-coding TIMP3 variants in relation to common polygenic age-related macular degeneration, rs121918348 represents a rare, high-penetrance monogenic driver rather than a modest polygenic risk factor.
Clinical Context and Navigating Genetic Findings
Genetic identification of rs121918348 provides diagnostic clarity but requires careful interpretation in a clinical genetics setting. A finding of this variant in direct-to-consumer data should be treated with caution, as rare variants on array platforms suffer high false-positive rates and require independent validation via clinical-grade Sanger or next-generation sequencing. Genetic test results cannot replace an ophthalmic examination. For individuals confirmed to carry the variant, regular surveillance by a retinal specialist is essential to detect choroidal neovascular membranes early. Contemporary therapies such as intravitreal anti-VEGF injections do not reverse the underlying genetic defect, but clinical evidence indicates they can help mitigate acute vision loss from secondary neovascularization if administered promptly.
How common is this variant?
The rs121918348 variant is exceptionally rare across all ancestries, displaying an allele frequency below 0.00001 in gnomAD, with virtually all individuals globally exhibiting the homozygous reference genotype.
Frequently asked questions
What is Sorsby fundus dystrophy?
Sorsby fundus dystrophy is a rare, inherited eye condition that causes progressive loss of central vision, usually starting around age 35 to 45. It is marked by a thickening of Bruch's membrane beneath the retina and often leads to sudden central vision changes due to abnormal blood vessel growth.
How is Sorsby fundus dystrophy inherited?
The condition follows an autosomal dominant pattern of inheritance. This means inheriting just one copy of the altered TIMP3 gene from either parent is typically sufficient to cause the condition.
Is rs121918348 the same as common age-related macular degeneration (AMD)?
No. While Sorsby fundus dystrophy shares clinical similarities with wet age-related macular degeneration, it is caused by high-penetrance monogenic mutations like rs121918348 and typically appears much earlier in life, whereas AMD is generally a late-onset, complex disease influenced by multiple genes and lifestyle factors.
Can vision loss from TIMP3 mutations be managed?
Although the underlying genetic change cannot be cured, modern ophthalmic treatments such as anti-VEGF eye injections are frequently used off-label to slow down or control secondary choroidal neovascularization, helping preserve central vision if caught early.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121918348?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TIMP3
Encodes the Ser181Cys mutation in TIMP3, a classic pathogenic driver of Sorsby fundus dystrophy leading to premature macular choroidal neovascularization.
Pathogenic missense substitution (p.Ser181Cys) in TIMP3 causing Sorsby fundus dystrophy, leading to choroidal neovascularization and macular degeneration.
Variant in the TIMP3 signal sequence region associated with abnormal cleavage and atypical macular dystrophy.